Skip to main content

Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models.

Publication ,  Journal Article
Parker, S; McDowall, C; Sanchez-Perez, L; Osorio, C; Duncker, PC; Briley, A; Swartz, AM; Herndon, JE; Yu, Y-RA; McLendon, RE; Tedder, TF ...
Published in: Sci Transl Med
February 8, 2023

D2C7-immunotoxin (IT), a dual-specific IT targeting wild-type epidermal growth factor receptor (EGFR) and mutant EGFR variant III (EGFRvIII) proteins, demonstrates encouraging survival outcomes in a subset of patients with glioblastoma. We hypothesized that immunosuppression in glioblastoma limits D2C7-IT efficacy. To improve the response rate and reverse immunosuppression, we combined D2C7-IT tumor cell killing with αCD40 costimulation of antigen-presenting cells. In murine glioma models, a single intratumoral injection of D2C7-IT+αCD40 treatment activated a proinflammatory phenotype in microglia and macrophages, promoted long-term tumor-specific CD8+ T cell immunity, and generated cures. D2C7-IT+αCD40 treatment increased intratumoral Slamf6+CD8+ T cells with a progenitor phenotype and decreased terminally exhausted CD8+ T cells. D2C7-IT+αCD40 treatment stimulated intratumoral CD8+ T cell proliferation and generated cures in glioma-bearing mice despite FTY720-induced peripheral T cell sequestration. Tumor transcriptome profiling established CD40 up-regulation, pattern recognition receptor, cell senescence, and immune response pathway activation as the drivers of D2C7-IT+αCD40 antitumor responses. To determine potential translation, immunohistochemistry staining confirmed CD40 expression in human GBM tissue sections. These promising preclinical data allowed us to initiate a phase 1 study with D2C7-IT+αhCD40 in patients with malignant glioma (NCT04547777) to further evaluate this treatment in humans.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Sci Transl Med

DOI

EISSN

1946-6242

Publication Date

February 8, 2023

Volume

15

Issue

682

Start / End Page

eabn5649

Location

United States

Related Subject Headings

  • Mice
  • Immunotoxins
  • Humans
  • Glioma
  • Glioblastoma
  • ErbB Receptors
  • Cell Line, Tumor
  • CD8-Positive T-Lymphocytes
  • Brain Neoplasms
  • Animals
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Parker, S., McDowall, C., Sanchez-Perez, L., Osorio, C., Duncker, P. C., Briley, A., … Chandramohan, V. (2023). Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models. Sci Transl Med, 15(682), eabn5649. https://doi.org/10.1126/scitranslmed.abn5649
Parker, Scott, Charlotte McDowall, Luis Sanchez-Perez, Cristina Osorio, Patrick C. Duncker, Aaron Briley, Adam M. Swartz, et al. “Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models.Sci Transl Med 15, no. 682 (February 8, 2023): eabn5649. https://doi.org/10.1126/scitranslmed.abn5649.
Parker S, McDowall C, Sanchez-Perez L, Osorio C, Duncker PC, Briley A, et al. Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models. Sci Transl Med. 2023 Feb 8;15(682):eabn5649.
Parker, Scott, et al. “Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models.Sci Transl Med, vol. 15, no. 682, Feb. 2023, p. eabn5649. Pubmed, doi:10.1126/scitranslmed.abn5649.
Parker S, McDowall C, Sanchez-Perez L, Osorio C, Duncker PC, Briley A, Swartz AM, Herndon JE, Yu Y-RA, McLendon RE, Tedder TF, Desjardins A, Ashley DM, Gunn MD, Enterline DS, Knorr DA, Pastan IH, Nair SK, Bigner DD, Chandramohan V. Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models. Sci Transl Med. 2023 Feb 8;15(682):eabn5649.

Published In

Sci Transl Med

DOI

EISSN

1946-6242

Publication Date

February 8, 2023

Volume

15

Issue

682

Start / End Page

eabn5649

Location

United States

Related Subject Headings

  • Mice
  • Immunotoxins
  • Humans
  • Glioma
  • Glioblastoma
  • ErbB Receptors
  • Cell Line, Tumor
  • CD8-Positive T-Lymphocytes
  • Brain Neoplasms
  • Animals